Pharma Industry

The dispute involved payments made by Ranbaxy, now merged with Sun Pharmaceutical Industries Ltd, to Teva Israel under a 2011 settlement relating to the US launch of generic atorvastatin.

The Harsh Goenka group is spending to build a drug-ingredients business, betting that the world's push to rely less on China will favour Indian makers.

Delhi High Court ordered Sun Pharma to seek judicial approval before launching semaglutide tablets, following a patent infringement suit by Novo Nordisk. The order requires Sun Pharma to return to court once it secures a manufacturing licence.

This American pharma major wants to end its nightmare of lawsuits over allegations of ovarian cancer-causing talcum powder. But its therapeutic advances—in oncology, especially—might determine whether it can rescue J&J as a brand.

The US is India’s largest pharmaceutical export market, accounting for $9.47 billion, or 30.4%, of the country’s total pharmaceutical exports of $31.12 billion in FY26, making the proposed tariffs one of the biggest risks facing the sector.

Suven has one of the deepest innovation pipelines in the country, solely focused on central nervous system disorders.

The deal may value Olive PharmaScience at around ₹4,500 crore.

For chairman Glenn Saldanha, the way forward is a mix of licensing deals, partnerships and Glenmark’s own commercialization in emerging markets.

The move spotlights India's dominance in legal opium production and its ability to supply one of the world's most tightly regulated essential medicines.